MB MAINLINE BIOSCIENCES
Live / Registered — Registered (as of 29 Jul 2025)
What this means for you
Registered since 29 Jul 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97682024
- Registration number
- 7874388
- Mark type
- Word mark
- Filed
- 17 Nov 2022
- Published for opposition
- 04 Jun 2024
- Registered
- 29 Jul 2025
- Attorney of record
- Don D. Cha
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention of cancer or tumor; Pharmaceutical preparations for the treatment and prevention of cancer or tumor; Pharmaceutical preparations for the treatment of cancer or tumor; Pharmaceutical preparations for cancer or tumor; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer or tumor
Owner
- Mainline Biosciences (Shanghai) Co., Ltd., Lingang, Shanghai, CN
- Mainline Biosciences (Shanghai) Co., Ltd., Lingang, Shanghai, CN
- Mainline Biosciences (Shanghai) Co., Ltd., Lingang, Shanghai, CN
Prosecution history
- 29 Jul 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 29 Jul 2025 — REGISTERED-PRINCIPAL REGISTER
- 16 Jul 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 07 Jul 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 07 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
- 07 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 07 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
- 07 Jul 2025 — SU-EXAMINER'S AMENDMENT WRITTEN
- 26 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Feb 2025 — NON-FINAL ACTION E-MAILED
- 26 Feb 2025 — SU - NON-FINAL ACTION - WRITTEN
- 12 Feb 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 30 Nov 2024 — USE AMENDMENT FILED
- 12 Feb 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Nov 2024 — TEAS STATEMENT OF USE RECEIVED